Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial
Listen to this summary
This study aimed to determine whether empirical treatment with valganciclovir improves survival in infants with severe HIV-associated pneumonia in Africa. The trial found that while there was no significant difference in mortality rates at 15 days or 12 months between those receiving valganciclovir and those who did not, the treatment was associated with a lower hazard of death over time, suggesting a potential benefit without increased adverse effects.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Jul 23, 2026 · Lancet (London, England)
Oral step-down, optimal drug, and total duration of antibiotic treatment in African children hospitalised with severe community-acquired pneumonia (PediCAP): a factorial randomised controlled trial
Jul 22, 2026 · Lancet (London, England)
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial
Jul 15, 2026 · Lancet (London, England)
1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial
Jul 13, 2026 · Lancet (London, England)
Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial
Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
More in Nuclear Medicine
View all →Jul 22, 2026 · The New England journal of medicine
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Jul 22, 2026 · The New England journal of medicine
Antiretroviral Therapy
Jul 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Incremental prognostic value of the hemodynamic gain index in patients undergoing exercise stress myocardial perfusion imaging
Jul 15, 2026 · The New England journal of medicine
Andes Virus - A Clinical Review
Jul 15, 2026 · The New England journal of medicine
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
Jul 15, 2026 · The New England journal of medicine
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
